Neuro-ID Introduces Frictionless Identity Screening Products to Help Solve the “Digital Identity Crisis”
16.2.2022 14:00:00 CET | Business Wire | Press Release
Neuro-ID, the pioneers in the field of behavioral analytics, today launched its ID Crowd Alert™ and ID Orchestrator™ products to help digital organizations screen identity at scale, optimize orchestration and enhance fraud detection. Working in tandem with identity platforms and enterprise clients that require the highest levels of identity screening – including KYC, AML and fraud stacks,the products add powerful new visibility into pre-submit behavioral data to deliver better identity decisioning.
“Recent headlines underscore the tidal wave of identity fraud that impacts both large and small companies across the globe. Until now, limited visibility into crowd-level- and applicant-level-behavior has made it impossible to maintain a proper balance between fraud screening without detracting from an exceptional customer experience,” said Jack Alton, CEO at Neuro-ID. “Our two new products offer a one-two punch to address this imbalance. ID Crowd Alert provides the industry's first proactive monitoring and alerting for fraud rings and BoT attacks, and our ID Orchestrator product screens applicant-level identity at scale to deliver broad visibility into pre-submit behavior and the manner in which a customer has entered their PII. Together, the solutions help companies stem fraud-related losses while also safeguarding their most valuable asset: the customer onboarding funnel.”
Identity platforms and enterprise fraud systems have been stretched to their limit, unable to keep up with the pace of fraud without hindering the customer experience and sales. According to a recent Aite’Novarica survey1, 50% of FI compliance and AML executives reported false positives as their top concern, followed by KYC/CCD onboarding (27%) as their second most pressing pain point. This leaves genuine applicants being subjected to additional security screening, a costly manual reviews process, or outright rejected due to a lack of data. The situation creates a poor customer experience, which leads to abandonment and less than optimal conversion rates. Thus, the digital identity crisis.
“Neuro-ID’s new products offer another level of intelligence that helps our clients better orchestrate identity verification,” said Alloy CEO and co-founder Tommy Nicholas. “The ability to see risk through the lens of behavior, within pre-submit data, that does not rely on legacy streams of static data, is an important new element for consideration when our clients are determining how best to respond and treat each customer.”
Following a recent $35M Series B round of funding, led by Canapi Ventures, these breakthrough products use patented behavior analytics and intent detection technology. Neuro-ID continues to boost the performance of legacy systems for fraud detection, identity orchestration and customer experience optimization.
For more information, visit www.neuro-id.com.
About Neuro-ID
Neuro-ID delivers critical new behavioral insight to optimize identity orchestration and continually monitor crowd-level behavior to detect sophisticated fraud attacks. For digital-first organizations, this real-time behavioral intelligence is used during the digital onboarding process to segment genuine from fraudulent customers, to maximize conversion, reduce false positives and stop sophisticated fraud. Neuro-ID is committed to shaping the digital transformation in positive ways, by helping recapture critical human elements lost when business moved online. Visit Neuro-ID.com for more information.
[1] Aite’Novarica Survey: Key Trends Driving AML Compliance Transformation in 2022 and Beyond
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220216005364/en/
Contact information
Lexie Matinog
lexie@dottedlinecomm.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press Release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press Release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
